Navigation Links
Plavix(R) Indications Expanded in Japan to Include Patients with Acute Coronary Syndrome for Whom Percutaneous Coronary Intervention Is Being Planned
Date:10/21/2007

Japan, Plavix(R) is the only widely approved antiplatelet agent used in monotherapy for prevention of atherothrombotic events in patients with recent myocardial infarction (hear attack), recent ischaemic stroke or established peripheral arterial disease, and in combination with acetylsalicylic acid for the treatment of patients with acute coronary syndrome (unstable angina or NSTEMI) including those who are to be managed medically and those managed with PCI (with or without stent) and for STEMI patients.

Plavix(R) is one of the most studied cardiovascular medications available to patients with short and long term clinical benefit, and after a decade of prescriptions, it remains the oral antiplatelet therapy with the broadest range of indications worldwide.

About Plavix(R)

Plavix(R), also marketed as Iscover(R), is an antiplatelet agent which prevents platelets from sticking together and forming clots in the arteries. Plavix(R) was first authorized in the United States in 1997 and the European Union in 1998 and has been prescribed to more than 70 millions patients worldwide.

In Japan, in addition to the new approval for acute coronary syndrome (unstable angina pectoris, non-ST elevation myocardial infarction) for which percutaneous coronary intervention (PCI) is planned, Plavix(R) is also approved for "reduction of recurrence after ischemic cerebrovascular disorder (excluding cardiogenic cerebral embolism)" one of the 3 major causes of death in Japan.

The efficacy and safety profile of Plavix(R) have been established through landmark clinical trials including more than 100,000 patients worldwide. Outside Japan, Plavix(R) has shown favourable tolerability profile as compared to ASA and an acceptable increase in major bleedings when used in combination with ASA (no statistical difference when only PCIs are considered).

In Japan, Plavix(R) is marketed by sanofi-aventis K.K. Plavix(R) is marketed in more than 100 countries by sanofi-a
'/>"/>

SOURCE sanofi-aventis
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Othera Pharmaceuticals Announces Upcoming Presentation Based Upon Expanded Understanding of Lead Compound Mechanism of Action
2. Vical Licensee AnGes MG Announces Positive Results of Phase 3 Angiogenesis Trial in Japan
3. First Controlled Large-Scale Intervention Angiotensin Receptor Blocker (ARB) Trial in a Japanese Population, JIKEI HEART Study Demonstrates Significant Reduction in Blood Pressure and Protection of Organs with Valsartan
4. LANI completes Phase I in Japan and to commence Phase I in UK
5. AEterna Zentaris Reports Positive Results with Cetrorelix in BPH for Japanese Phase 2a Trial
6. New Data from the US and Japan Support: No Established Causal Link Between Neuropsychiatric Symptoms and Treatment with Tamiflu US Databases Indicate Psychiatric Symptoms Lower in Influenza Patients Taking Tamiflu Versus Those Not Taking Tamiflu
7. Hematology Analyzers Simple, Sophisticated Technology Serving All Patients
8. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
9. International ENDORSE Study Shows That the Majority of Hospitalized Patients Surveyed are at Risk for VTE and Many do not Receive Recommended VTE prophylaxis
10. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
11. New Study Shows That Extending Prophylaxis With Clexane / Lovenox (enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10 Days for Reducing the Risk of Venous Thromboembolism (VTE) in Acutely ill Medical Patients With Reduced Mobility
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... Shire plc (LSE: SHP, NASDAQ: SHPG ) announces ... condition to the announced tender offer for all of the outstanding ... result of the waiver, the transaction is no longer conditional on ... January 24, 2014 following the currently scheduled expiration time, subject to ...
(Date:1/15/2014)... PALM BEACH GARDENS, Fla. , Jan. 15, 2014  In an ... C. difficile and TB in ambulances and other transport vehicles, an ... being used by rescue personnel for the first time. ... coming in contact with these deadly pathogens, West Palm ...
(Date:1/15/2014)... The Cadence Fitness & Health Center has been ... Fitness Association, a non-profit organization assisting medically integrated health ... Cadence Fitness & Health Center is the only certified ... the Chicagoland area. "The certification means the ...
Breaking Medicine Technology:Shire Waives OFT Condition Relating to the Acquisition of ViroPharma Inc. 2Shire Waives OFT Condition Relating to the Acquisition of ViroPharma Inc. 3Superbugs No Longer Ride In Rescue Vehicles 2Cadence Fitness & Health Center Certified as Medical Fitness Facility 2Cadence Fitness & Health Center Certified as Medical Fitness Facility 3
(Date:7/10/2014)... Huddersfield could help to improve the quality of some ... as butter, mayonnaise, yoghurt and fruit drinks and ... her work. , Katerina gained her MSc degree in ... she has embarked on research for a PhD. ... investigating the potential of carbohydrates extracted from the pods ...
(Date:7/10/2014)... review identifying the clinical indicators most strongly associated with ... of developing evidence-based guidelines for concussion diagnosis, prognosis, and ... Neurosurgery , official journal of the ... published by Lippincott Williams & Wilkins , a ... , Based on analysis of the best available research ...
(Date:7/10/2014)... For decades, health-conscious people around the globe have ... figuring this was one of the paths to good ... clinical trials of antioxidant supplements have repeatedly dashed the ... their cancer risk. Virtually all such trials have ... In fact, in several trials antioxidant supplementation has been ...
(Date:7/10/2014)... Researchers at sarcomas research group at the Bellvitge Biomedical ... (ICO) have been tested in 19 patients a new ... results, which indicate that the new treatment could stabilize ... week in the British Journal of Cancer ., ... tumor and complex since there are several subtypes. It ...
(Date:7/10/2014)... that a new drug could prove useful in treating small ... cancer. , Scientists from the Cancer Research UK Manchester Institute, ... Manchester Cancer Research Centre, teamed up with experts at AstraZeneca, ... a drug known as AZD3965 - on small cell ... Clinical Cancer Research , also helps identify which patients ...
Breaking Medicine News(10 mins):Health News:World interest in research work on the benefits of the Okra plant 2Health News:What's a concussion? Review identifies four evidence-based indicators 2Health News:What's a concussion? Review identifies four evidence-based indicators 3Health News:How antioxidants can accelerate cancers, and why they don't protect against them 2Health News:New therapeutic combination to slow resistant sarcomas 2Health News:New drug active against most aggressive type of lung cancer cells 2
... baby to a 3D ultrasound imaging session offered by private ... advice has been offered by medical experts, in the wake ... of the unborn child. ,It is no longer news ... ultrasound machine in 2005, so that they could monitor their ...
... drugs have a high proportion of viral strains that can ... to a study published in the February 15th edition of ... Timothy J Wilkin of Weill-Cornell Medical College, New York, also ... (known as dual-tropic virus) had lower CD4 cell counts than ...
... Medical Center is one of the first medical centers ... Illinois, participating in a novel clinical trial to// determine ... form of severe coronary artery disease. ,The ... the first human, Phase II adult stem cell therapy ...
... prisoner, otherwise calm, had suddenly turned awry. Guards in ... Apparently, the prisoner had been consuming from a gallon ... ,The alarm regarding abuse of hand sanitizers was ... Control Center, Dr. Suzanne Doyon, who has sought to ...
... A review of data available on most of the ... the prevalence of Multiple Sclerosis// and Alzheimer’s diseases had ... one out of 1,000 people have multiple sclerosis (MS). ... higher than a comprehensive review from 1982. Whether this ...
... in Chicago has launched a leukaemia awareness campaign and ... suffering// from the disease. ,Steve Hill, a ... coming to know that Nikit Patel, the 22-year-old son ... diagnosed with acute myelogenous leukaemia (AML)., ,AML ...
Cached Medicine News:Health News:Mixed HIV Coreceptor Use Associated With Lower CD4 Count 2Health News:Mixed HIV Coreceptor Use Associated With Lower CD4 Count 3Health News:Mixed HIV Coreceptor Use Associated With Lower CD4 Count 4Health News:Potential for Adult Stem Cells to Repair Hearts Damaged Investigated 2Health News:Potential for Adult Stem Cells to Repair Hearts Damaged Investigated 3Health News:Incidence of Neurological Disorders on the Rise 2Health News:US Student Raising Funds For Cancer-Ridden Indian American 2
Clearview RSV is a simple, immunochromatographic assay to aid in the diagnosis of respiratory syncytial virus (RSV) infections in children less than 6 years and adults over age 60....
Clearview ULTRA FOB is a rapid, two-step immunochemical test for the detection of fecal occult blood....
... RTVue is an ultra-high speed, high resolution ... for retina imaging and analysis. ... Fourier-Domain Optical Coherence technology just emerging from ... The ultra-high speed and high ...
The Clearview hCG Test is for the rapid detection of human chorionic gonadotropin (hCG) in urine specimens. This test kit is used to obtain a visual, qualitative result and is intended for professio...
Medicine Products: